Alkermes plc
Alkermes plc is a biopharmaceutical company that develops pharmaceutical products for unmet medical needs. It has a portfolio of proprietary products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Marketed products include ARISTADA, ARISTADA INITIO, VIVITROL, and LYBALVI. The company has collaboration agreements with Janssen Pharmaceutica companies. Alkermes also offers technology platforms to third parties. Founded in 1987, the company is headquartered in Dublin, Ireland.
Overview
Strengths
- Creates economic value: ROIC of 17.9% against a cost of capital (WACC) of 4.5%, a spread of 13.5 percentage points.
- High-quality earnings: over the last 7 years, free cash flow added up to 292% of reported net income.
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/FCF 15.8x vs. a median of 21.4x.
- ROIC of 17.9% beats 78% of its 55 Drug Manufacturers - Specialty & Generic peers (median 10.9%).
- Cheaper than its own history: P/FCF 15.8x vs. a historical average of 53.5x.
Weaknesses
- Our discounted cash flow target price (19.96 USD) is 57% below the current price.
- Unstable profitability: operating margin ranged from -14% to 27% over the last 7 years, with operating losses in 3 of them.
- Valued at a premium to its Drug Manufacturers - Specialty & Generic peers: P/E 31.5x vs. a median of 19.6x and EV/EBITDA 25.1x vs. a median of 12.5x.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data